aim.jpg
Aimfinity Investment Corp. I Announces Eighth Extension of the Deadline for an Initial Business Combination to April 28, 2024
March 28, 2024 17:00 ET | Aimfinity Investment Corp. I
Wilmington, Delaware, , March 28, 2024 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company incorporated as a Cayman...
Verve-Logo-RGB-Color-wTrademark.png
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024 16:51 ET | Verve Therapeutics
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
logo_500x500.png
Bitdeer Reports Financial Results for the Full Year 2023 and Operational Update
March 28, 2024 16:45 ET | Bitdeer Technologies Group
SINGAPORE, March 29, 2024 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance...
TMT Acquisition Corp Announces Adjournment of Extraordinary General Meeting
March 28, 2024 16:44 ET | TMT Acquisition Corp
New York, New York, March 28, 2024 (GLOBE NEWSWIRE) -- TMT Acquisition Corp (Nasdaq: TMTCU, TMTC, and TMTCR) (the “Company”) announced today that the extraordinary general meeting originally...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 28, 2024 16:32 ET | Zevra Therapeutics
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M ...
Applied Therapeutics logo.jpg
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
March 28, 2024 16:30 ET | Applied Therapeutics
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
pyxis logo.jpg
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024 16:30 ET | Pyxis Oncology
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Shapeways.png
Shapeways Reports Fourth Quarter and Full Year 2023 Results
March 28, 2024 16:29 ET | Shapeways, Inc.
- Expands Q4 2023 Gross Margins to 46% and Increases Gross Profit by 23% vs the same quarter in the prior year -- Continues to Explore Strategic Alternatives to Maximize Shareholder Value - NEW YORK,...
logo.png
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
March 28, 2024 16:28 ET | Centessa Pharmaceuticals plc
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist...
NaaS Technology Inc. Reports Unaudited 2023 Fourth Quarter and Full Year Financial Results
March 28, 2024 16:15 ET | NaaS Technology Inc.
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- NaaS Technology Inc. (“NaaS” or the “Company”) (Nasdaq: NAAS), the first U.S. listed EV charging service company in China, today announced its unaudited...